Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

NCT00099216 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00099216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2001
Completion date
November 30, 2005
Enrollment
708 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

vascular dementia